Immunotherapy Yields Benefits in Select Extensive-Stage SCLC Populations
March 2nd 2024FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.